# CORTEXIA Funding Timeline & Roadmap

**Strategic Goal:** NIH R01 eligibility by December 2026
**Current Status:** Pre-grant phase (building track record)

---

## üìÖ Master Timeline (2025-2027)

```
2025 Q1 (Jan-Mar)
‚îú‚îÄ‚îÄ Validate CORTEXIA on public datasets
‚îú‚îÄ‚îÄ Generate preliminary results
‚îî‚îÄ‚îÄ Identify collaborators

2025 Q2 (Apr-Jun)
‚îú‚îÄ‚îÄ Submit first publication (preprint)
‚îú‚îÄ‚îÄ Secure institutional affiliation
‚îî‚îÄ‚îÄ Begin R21 preparation

2025 Q3 (Jul-Sep)
‚îú‚îÄ‚îÄ Publication under review
‚îú‚îÄ‚îÄ R21 grant submission (Sep 30)
‚îî‚îÄ‚îÄ NSF CISE application (backup)

2025 Q4 (Oct-Dec)
‚îú‚îÄ‚îÄ R21 under review
‚îú‚îÄ‚îÄ Second publication in progress
‚îî‚îÄ‚îÄ Clinical collaboration established

2026 Q1 (Jan-Mar)
‚îú‚îÄ‚îÄ R21 award notification (target)
‚îú‚îÄ‚îÄ Begin R21 project execution
‚îî‚îÄ‚îÄ Third publication submitted

2026 Q2-Q4
‚îú‚îÄ‚îÄ R21 execution (preliminary clinical data)
‚îú‚îÄ‚îÄ Publications 3-5
‚îî‚îÄ‚îÄ Build track record for R01

2027 Q1
‚îî‚îÄ‚îÄ R01 SUBMISSION READY
```

---

## üéØ Milestone Tracking

### Phase 1: Foundation (2025 Q1-Q2)
**Goal:** Establish credibility & preliminary data

| Milestone | Target Date | Status | Dependencies |
|-----------|-------------|--------|--------------|
| HCP dataset analysis | 2025-03-31 | üü° In Progress | Dataset download |
| Allen Brain validation | 2025-04-15 | üîµ Planned | Dataset access |
| First publication draft | 2025-05-15 | üîµ Planned | Validation results |
| bioRxiv submission | 2025-06-15 | üîµ Planned | Draft complete |
| Adjunct position secured | 2025-07-15 | üîµ Planned | Negotiation |

**Success Criteria:**
- ‚úÖ 1 preprint published
- ‚úÖ Validation on 2+ datasets
- ‚úÖ Institutional affiliation

---

### Phase 2: First Grant Submissions (2025 Q3-Q4)
**Goal:** Secure first research funding

| Grant | Amount | Submission | Decision | Probability |
|-------|--------|------------|----------|-------------|
| NIH R21 | $275K | 2025-09-30 | 2025-12-31 | 15-20% |
| NSF CISE | $350K | 2025-10-15 | 2026-03-31 | 20% |
| SBIR Phase I | $250K | 2025-11-15 | 2026-02-28 | 25% |
| AWS Credits | $100K | 2025-08-01 | 2025-09-15 | 40% |

**Backup Strategy:**
- Apply to multiple grants simultaneously
- At least 1 award expected (combined probability ~50%)
- If R21 successful ‚Üí primary path to R01
- If NSF successful ‚Üí alternate path, still competitive

---

### Phase 3: Track Record Building (2026)
**Goal:** Publications + Active Funding + Collaborations

**Publications Target (3-5 papers):**

| Paper | Journal | Topic | Submission | Status |
|-------|---------|-------|------------|--------|
| 1 | PLOS Comp Bio | CORTEXIA Framework | 2025-06-15 | üîµ Planned |
| 2 | Frontiers Neuro | IIT Validation (HCP) | 2026-01-15 | üîµ Planned |
| 3 | eLife | Anesthesia Œ¶ Trajectories | 2026-06-15 | üîµ Planned |
| 4 | J Neurosci Methods | Real-time Œ¶ Pipeline | 2026-09-15 | üîµ Planned |
| 5 | Network Neuroscience | TDA + Consciousness | 2026-12-15 | üîµ Planned |

**Funding Status:**
- R21 active (months 1-24)
- AWS/Cloud credits supporting compute
- Possible industry partnership

**Collaborations:**
- 2-3 academic labs (EEG, fMRI)
- 1 clinical collaborator (hospital)
- Industry partner (optional)

---

### Phase 4: R01 Preparation (2026 Q4 - 2027 Q1)
**Goal:** Competitive R01 application

**R01 Requirements Checklist:**

- [ ] **Publications:** 3-5 peer-reviewed papers (first/senior author)
- [ ] **Prior Funding:** R21 active (or completed)
- [ ] **Preliminary Data:** Clinical pilot study (n‚â•10)
- [ ] **Collaborators:** 3-5 confirmed (letters of support)
- [ ] **Institutional Support:** Strong affiliation + resources
- [ ] **Track Record:** Proven feasibility + impact

**R01 Application Timeline:**
```
2026-10: Begin R01 preparation
2026-11: Draft specific aims
2026-12: Write research strategy
2027-01: Finalize budget & letters
2027-02: R01 SUBMISSION
2027-06: Anticipated decision
```

---

## üí∞ Funding Cascade Strategy

### Tier 1: Quick Wins (3-6 months)
- **AWS Cloud Credits** ($100K) - 40% probability
- **Google Research Scholar** ($60K) - 15% probability
- **Microsoft Azure Credits** ($100K) - 30% probability

**Total Expected:** ~$100K compute resources

---

### Tier 2: First Grant (6-12 months)
- **NIH R21** ($275K, 2 years) - 15-20% probability
- **NSF CISE** ($350K, 3 years) - 20% probability
- **SBIR Phase I** ($250K, 1 year) - 25% probability

**Total Expected:** $250-350K (50% probability ‚â•1 award)

---

### Tier 3: Major Funding (18-30 months)
- **NIH R01** ($350K/year √ó 5 years) - 10-15% probability (with R21)
- **NSF NeuroNex** ($1-3M, 5 years) - 8-12% probability
- **DARPA** ($1-5M, 3 years) - 5-10% probability

**Total Expected:** $1.75-2.5M (if R01 awarded)

---

## üìä Probability Analysis

### Scenario 1: Optimal Path (30% probability)
```
2025 Q3: R21 awarded ($275K)
2026:    Publications 2-5, clinical data
2027 Q2: R01 awarded ($1.75M)
Total:   $2M+ over 7 years
```

### Scenario 2: NSF Path (25% probability)
```
2025 Q4: NSF CISE awarded ($350K)
2026:    Publications 2-4
2027 Q3: R01 awarded (with NSF track record)
Total:   $2.1M over 8 years
```

### Scenario 3: SBIR Path (20% probability)
```
2025 Q4: SBIR Phase I ($250K)
2026 Q2: SBIR Phase II ($1M)
2027:    Commercial product, no R01 needed
Total:   $1.25M + commercial revenue
```

### Scenario 4: Foundation Path (15% probability)
```
2026 Q1: Templeton Foundation ($300K)
2026:    Publications + international collaboration
2027 Q4: ERC Grant (Europe) or NIH R01
Total:   $1.5-3M
```

### Scenario 5: Bootstrap Path (10% probability)
```
2025-2026: No major grants, cloud credits only
2026 Q4:   First publication gains visibility
2027 Q2:   Industry partnership or late R01
Total:     $500K-1M + equity/partnership
```

**Combined probability of ‚â•$250K funding by 2026:** ~80%
**Combined probability of ‚â•$1M funding by 2027:** ~50%

---

## üéì Academic Milestones

### Publications (Critical Path)

**Minimum for R01 Competitiveness:**
- 3 peer-reviewed papers (first or senior author)
- 2+ in high-impact journals (IF >5)
- 1 methodological paper (CORTEXIA framework)
- 1 validation paper (real data)
- 1 application paper (clinical or cognitive)

**Citation Impact:**
- Target: 20-50 citations total by 2027
- Key: Framework paper should be highly cited tool

---

### Presentations

**Conferences (2025-2027):**
- Society for Neuroscience (SfN) - Annual
- Cognitive Neuroscience Society (CNS)
- Association for the Scientific Study of Consciousness (ASSC)
- NIH BRAIN Initiative Meeting
- Computational Neuroscience (Cosyne/CNS)

**Target:** 1-2 presentations per year

---

## ü§ù Collaboration Development

### Year 1 (2025)
- Identify 5-10 potential collaborators
- Establish 1-2 active collaborations (data sharing)
- Co-author 1 paper

### Year 2 (2026)
- Expand to 3-4 active collaborations
- Multi-site data collection (clinical)
- Co-PI on collaborative proposal

### Year 3 (2027)
- Established network (5+ collaborators)
- Multi-center R01 application
- International partnerships

---

## üìà Progress Metrics

### Quarterly KPIs

**Q1 2025:**
- [ ] Datasets analyzed: 2
- [ ] Preprints submitted: 1
- [ ] Collaborators contacted: 10

**Q2 2025:**
- [ ] Publications submitted: 1
- [ ] Institutional affiliation: Yes
- [ ] Grant applications: 1

**Q3 2025:**
- [ ] Grant submissions: 2-3
- [ ] Conference abstracts: 1
- [ ] Second paper draft: Complete

**Q4 2025:**
- [ ] Grant awards: 1+ expected
- [ ] Publications accepted: 1
- [ ] Clinical collaboration: Active

---

## üö® Risk Mitigation

### Risk 1: No Grants Awarded (2025)
**Mitigation:**
- Resubmit with reviewer feedback
- Apply to alternate programs (foundations)
- Continue publication track
- Self-fund with consulting/services

### Risk 2: Publication Rejections
**Mitigation:**
- Submit to multiple journals (cascading IF)
- Use preprints for grant applications
- Ensure technical quality (reproducibility)

### Risk 3: Collaboration Falls Through
**Mitigation:**
- Multiple collaborator pipeline
- Public datasets as backup
- Focus on computational strengths

### Risk 4: Institutional Support Loss
**Mitigation:**
- Multiple institutional affiliations
- Remote collaboration agreements
- Industry partnerships as alternative

---

## ‚úÖ Decision Points

### March 2025: Continue or Pivot?
**If preliminary data looks weak:**
- Pivot to pure computational methods paper
- Focus on algorithmic innovations
- Target CS journals instead

**If preliminary data is strong:**
- Proceed with neuroscience focus
- Target R21 submission
- Expand dataset validation

---

### December 2025: Funding Outcome
**If R21 awarded:**
- Execute R21 plan (primary path)
- Begin R01 preparation
- Hire postdoc/research assistant

**If no awards:**
- Resubmit R21 (February 2026 cycle)
- Focus on publications
- Seek foundation grants

---

### June 2026: R01 Decision
**If track record strong (3+ papers, R21 active):**
- Proceed with R01 submission (February 2027)
- Expand aims (multi-site clinical)
- Large budget ($1.75M+)

**If track record moderate (1-2 papers):**
- Delay R01 to 2027 Q4
- Focus on additional publications
- Alternative: NSF NeuroNex or ERC

---

## üìû Checkpoint Schedule

- **Monthly:** Review progress on current quarter KPIs
- **Quarterly:** Assess milestone completion, adjust timeline
- **Semi-Annually:** Major decision points (continue/pivot)
- **Annually:** Strategic review (funding status, publication record)

---

**Last Updated:** 2025-01-13
**Next Review:** 2025-02-15
**Status:** Active Planning
